Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Not Yet Opened 07-13 16:00:00 EDT

183.95

-2.93

-1.57%

盘后186.50

+2.55+1.39%

19:46 EDT

High186.00	Low180.10	Vol1.71M
Open182.78	D1 Closing186.88	Amplitude3.16%
Mkt Cap39.11B	Tradable Cap36.87B	Total Shares212.59M
T/O311.45M	T/O Rate0.85%	Tradable Shares200.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":183.95,"timestamp":1783972800000,"preClose":186.88,"halted":0,"volume":1705721,"hourTrading":{"tag":"盘后","latestPrice":186.5,"preClose":183.95,"latestTime":"19:46 EDT","volume":12512,"amount":2301489.8557,"timestamp":1783986384087,"change":2.55,"changeRate":0.013862,"amplitude":0.013862},"delay":0,"changeRate":-0.01567851027397264,"floatShares":200428539,"shares":212592561,"eps":-7.121384,"marketStatus":"Not Yet Opened","change":-2.93,"latestTime":"07-13 16:00:00 EDT","open":182.78,"high":185.998,"low":180.1,"amount":311450633.57338,"amplitude":0.03156,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.121384,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784016000000},"marketStatusCode":0,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":186.88,"preHourTrading":{"tag":"盘前","latestPrice":182.22,"preClose":186.88,"latestTime":"09:28 EDT","volume":1690,"amount":311468.5717,"timestamp":1783949280253,"change":-4.66,"changeRate":-0.024936,"amplitude":0.041631},"postHourTrading":{"tag":"盘后","latestPrice":186.5,"preClose":183.95,"latestTime":"19:46 EDT","volume":12512,"amount":2301489.8557,"timestamp":1783986384087,"change":2.55,"changeRate":0.013862,"amplitude":0.013862},"volumeRatio":0.922955,"impliedVol":0.5689,"impliedVolPercentile":0.5618},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"2650296159","title":"Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650296159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650296159?lang=en_us&edition=fundamental","pubTime":"2026-07-11 22:30","pubTimestamp":1783780221,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vera-therapeutics-vera-crinetics-pharmaceuticals-crnx-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vera-therapeutics-vera-crinetics-pharmaceuticals-crnx-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LABU","LU0029874061.USD","LU0128526141.USD","XBI","CRNX","PTH","XLV","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IDNA","IE00B2B36J28.USD","BK4539","CANC","BK4007","BK4585","BBH","BK4139","BK4137","RVMD","LU2324357040.USD","BK4588","HCSG","IE00B4R5TH58.HKD","IE0002141913.USD","LU0889565916.HKD","VERA","LU0109394709.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650871071","title":"Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650871071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650871071?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:01","pubTimestamp":1783684888,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-simulations-plus-slp-alnylam-pharma-alny-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-simulations-plus-slp-alnylam-pharma-alny-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY","LU0128526141.USD","HCSG","BK4581","SLP","XLV","IE0009355771.USD","LABU","IDNA","LU0882574055.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","RVMD","LU0889565916.HKD","XBI","CANC","IE0002141913.USD","PBE","IE00BFTCPJ56.SGD","BK4585","BK4548","IE00B2B36J28.USD","BK4139","BK4137","LU0029874061.USD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4167","BK4588","IE00B4R5TH58.HKD","LU0320765992.SGD","BBH","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650971920","title":"Revolution Medicines is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2650971920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650971920?lang=en_us&edition=fundamental","pubTime":"2026-07-09 22:21","pubTimestamp":1783606860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 10:21 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929985","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Satellos Bioscience (MSLE) and Intuitive Surgical (ISRG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929985?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:40","pubTimestamp":1783597212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD), Satellos Bioscience (MS...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-satellos-bioscience-msle-and-intuitive-surgical-isrg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-satellos-bioscience-msle-and-intuitive-surgical-isrg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","IE0002141913.USD","BBH","LU1057294990.SGD","LU1923622614.USD","LU0079474960.USD","LU0029874061.USD","LU0390134368.USD","LU0971096721.USD","LU0128526141.USD","LU1244550577.SGD","IAI","LU2265009873.SGD","LGHT","LU0889565916.HKD","LU1868836914.USD","XLV","IE00BYQQ9H92.USD","IE00BJJMRZ35.SGD","KBWB","ISUL","LU0795875169.SGD","LU0061475181.USD","HCSG","LU0557290698.USD","IDNA","LU1363072403.SGD","LU1668664300.SGD","LU0823416689.USD","XBI","EKG","LU1061106388.HKD","IHI","LU2106854487.HKD","ISRG","LU0267386448.USD","LU1244550494.USD","LU1720051017.SGD","PTH","LU2111349929.HKD","MSLE","LU2023250843.SGD","IE00B4R5TH58.HKD","LU2433249047.HKD","LU1951200564.SGD","LU0234570918.USD","LABU","LU0795875086.SGD","CANC","LU0158827781.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929965","title":"Revolution Medicines price target raised to $235 from $205 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929965?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:30","pubTimestamp":1783596647,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $235 from $205 and keeps a Buy rating on the sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-235-from-205-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-235-from-205-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650198039","title":"Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650198039","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650198039?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:26","pubTimestamp":1783542389,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) is back in focus after regulators in Europe and the U.S. moved daraxonrasib into accelerated review for pancreatic cancer, alongside early trial results for partner drug zoldonrasib in RAS G12D metastatic disease.\nSee our latest analysis for Revolution Medicines.\nAfter this regulatory and clinical progress, Revolution Medicines’ recent 30 day share price return of 27.63% and year to date share price return of 141.03% suggest strong momentum, while the 1 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-wins-faster-reviews-is-the-valuati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-wins-faster-reviews-is-the-valuati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861215975.USD","LU1720051108.HKD","LU1720051017.SGD","IE00B4R5TH58.HKD","LU2360107325.USD","LU1861214812.USD","IE0009355771.USD","IE00BZ199S13.USD","BK4588","LU0320765992.SGD","BK4605","ON","LU2357305700.SGD","BK4585","LU1854104046.USD","LU1978683503.SGD","BK4139","IE00BFMHRM44.USD","CANC","IE00B2B36J28.USD","RVMD","DCF","LU1861220033.SGD","LU0348723411.USD","LU0724618433.USD","LU0109394709.USD","LU0124384867.USD","PTH","LU1861219969.SGD","IDNA","LU1983260115.SGD","LU1548497426.USD","IE00BFTCPJ56.SGD","BK4141","LU2298322129.HKD","LU0889565916.HKD","LU1854103824.USD","IE00BD6J9T35.USD","IE00BJJMRZ35.SGD","BK4512","BBH","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650990862","title":"RASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2650990862","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650990862?lang=en_us&edition=fundamental","pubTime":"2026-07-09 00:31","pubTimestamp":1783528295,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Revolution Medicines, Inc. (RVMD) is running a Phase 3 stud...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rasolute-305-rvmd-targets-kras-g12d-pancreatic-cancer-in-a-pivotal-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rasolute-305-rvmd-targets-kras-g12d-pancreatic-cancer-in-a-pivotal-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","LU0320765992.SGD","PTH","IDNA","CANC","IE00B4R5TH58.HKD","IE0002141913.USD","IE0009355771.USD","BBH","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0109394709.USD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649447938","title":"European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2649447938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649447938?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:23","pubTimestamp":1783430637,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA2FVX4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","BK4139","IE00B4R5TH58.HKD","CANC","LU0889565916.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","PTH","IE00B2B36J28.USD","LU0109394709.USD","IE0009355771.USD","RVMD","BBH","IE00BJJMRZ35.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649293833","title":"Revolution Medicines Rises as EU Regulator Starts Phased Review of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2649293833","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649293833?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:00","pubTimestamp":1783429226,"startTime":"0","endTime":"0","summary":"BUZZ-Revolution Medicines rises as EU regulator starts phased review of cancer drug** Shares of biotech firm Revolution MedicinesRVMD.Orise 1.3% to $192.42 premarket** European Medicines Agency says i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N43914J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE0009355771.USD","BK4139","IE00BJJMRZ35.SGD","PTH","LU0320765992.SGD","IE00B2B36J28.USD","RVMD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IDNA","CANC","BBH","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649980540","title":"EMA Fast Tracks Review of Medicine for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649980540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649980540?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:35","pubTimestamp":1783427704,"startTime":"0","endTime":"0","summary":"BRIEF-EMA Fast Tracks Review Of Medicine For Metastatic Pancreatic CancerJuly 7 (Reuters)-EMA:EMA - BEGINS PHASED REVIEW OF DARAXONRASIB FOR METASTATIC PANCREATIC CANCEREMA: FAST TRACKS REVIEW OF DARAXONRASIB FOR METASTATIC PANCREATIC CANCER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","LU0109394709.USD","RVMD","LU0320765992.SGD","IDNA","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BBH","IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","CANC","BK4139","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987702","title":"Ema - Begins Phased Review of Daraxonrasib for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987702?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:34","pubTimestamp":1783427642,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","IE00B2B36J28.USD","BK4139","LU0889565916.HKD","BBH","RVMD","IE00BFTCPJ56.SGD","PTH","IDNA","LU0320765992.SGD","CANC","IE00BJT1NW94.SGD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649247566","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), AxoGen (AXGN) and Eli Lilly & Co (LLY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649247566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649247566?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:10","pubTimestamp":1783343409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD), AxoGen (AXGN) and Eli L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-axogen-axgn-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-axogen-axgn-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0266013472.USD","LU1551013342.USD","VHT","IE0004445239.USD","IE00B2B36J28.USD","IXJ","LU1868837300.USD","LU2746668974.SGD","LU0823434583.USD","LU2237443549.SGD","LU2237443465.HKD","IE00BJJMRX11.SGD","LU2168564222.USD","SG9999017495.SGD","SGXZ57979304.SGD","LU0964807845.USD","BK4007","LU1712237335.SGD","LU1814569148.SGD","LU1917777945.USD","LU0198837287.USD","LU0820562030.AUD","LU0823434740.USD","SG9999018865.SGD","LU2108987350.USD","IE0001KFT4U8.USD","LU1629891620.HKD","LU1551013425.SGD","SGXZ51526630.SGD","LU2023250504.SGD","LU1057294990.SGD","LU0122379950.USD","LU1366192091.USD","LU0689472784.USD","LU0203202063.USD","IE00B775H168.HKD","BK4082","LU0210536198.USD","LU2360106947.USD","LU2602419157.SGD","LU1291159041.SGD","IE0005OL40V9.USD","LU2237443978.SGD","FTXH","LU0061475181.USD","LU1988902786.USD","LU2089284900.SGD","SG9999001176.USD","IE00B4JS1V06.HKD","LU2168564065.EUR","LU0316494557.USD","LU1232071149.USD","AGNG","LU0353189763.USD","BBH","LU0234572021.USD","IE00BK4W5M84.HKD","IE0004445015.USD","LU2357305700.SGD","LU0345770993.USD","LU0471298777.SGD","LU1868836591.USD","LU2063271972.USD","IE00B4R5TH58.HKD","LU2471134879.HKD","GB00BDT5M118.USD","IE00BJT1NW94.SGD","LU0203201768.USD","LU2461242641.AUD","LU0097036916.USD","LU2750360997.AUD","LU2896262040.SGD","LU0006306889.USD","SG9999015986.USD","LU2361044949.HKD","ELIS","LU1061106388.HKD","IDNA","BK4516","LU0323591593.USD","LU2756315318.SGD","LU2211815571.USD","LU0114720955.EUR","LU0158827948.USD","LU0820561909.HKD","LU2491050154.USD","LU0079474960.USD","LU2237438978.USD","LU2168563687.JPY","RXL","LU2324357040.USD","LU0238689110.USD","LU1023059063.AUD","BK4534","LU0289739699.SGD","BK4533","LU1720051108.HKD","LU2089984988.USD","LU2361044865.SGD","SG9999015945.SGD","LU1064131342.USD","LU2552382132.HKD","WDNA","LU0320765992.SGD","RVMD","IE00BK4W5L77.USD","LLY","LU2111349929.HKD","IE00BWXC8680.SGD","LU2756315664.SGD","LU0133085943.USD","BK4139","LU0058720904.USD","LU0889565916.HKD","LU2471134523.USD","PJP","BK4599","THNR","AXGN","PPH","IE00B1XK9C88.USD","LU0320765059.SGD","LU1035775433.USD","JDOC","OZEM","LU0096364046.USD","IE0009355771.USD","LU0106261372.USD","LU2264538146.SGD","LU0353189680.USD","LU2552382215.SGD","LU0432979614.USD","LU2271345857.HKD","LU1623119135.USD","LU2237443622.USD","LU2491049909.HKD","IE00BJLML261.HKD","LU0882574139.USD","LU0683600562.USD","IE00BFSS8Q28.SGD","LU1720051017.SGD","IE00BJJMRY28.SGD","SG9999001176.SGD","LU1280957306.USD","IYH","LU0820561818.USD","LU0256863902.USD","LU1323610961.USD","LU0471298694.HKD","LU2237443382.USD","LU1069344957.HKD","LU1868836757.USD","HRTS","CURE","LU2087625088.SGD","MEDI","GDOC","IE0002141913.USD","LU0672654240.SGD","LU0640476718.USD","SG9999014880.SGD","BK4588","LU0708995401.HKD","LU0109394709.USD","LU0466842654.USD","LU0787776722.HKD","LU1868836914.USD","LU2106854487.HKD","IE00BFSS7M15.SGD","LLYZ","LU0158827781.USD","LU0225283273.USD","LU2471134952.CNY","MEDX","IE00BJJMRZ35.SGD","IE00BN29S564.USD","LU1983299246.USD","SGXZ31699556.SGD","LU0786609619.USD","LU2750360641.GBP","LU1093756325.SGD","LU2237443895.HKD","SG9999018857.SGD","IE00B7KXQ091.USD","LU1989771016.USD","IE00BKDWB100.SGD","BK4585","FHLC","LU1267930730.SGD","LU2236285917.USD","SG9999014914.USD","LU1868837136.USD","LU2168564495.EUR","LU2028103732.USD","SG9999015952.SGD","LU0385154629.USD","SGXZ81514606.USD","LU2112291526.USD","LU2417539215.USD","SG9999014898.SGD","LU0456855351.SGD","LU1093756168.USD","LU0354030511.USD","LU0823416689.USD","PTH","LU0882574055.USD","IE00BKPKM429.USD","LU1127390331.HKD","LU0354030438.USD","ELIL","LU2213496289.HKD","LU2361045086.USD","LU2471134796.USD","LU0345770308.USD","IE00B1BXHZ80.USD","LU2023250330.USD","LLII","LU2265009873.SGD","LU2746668461.USD","LU1548497426.USD","LLYX","LU0417517546.SGD","ILDR","LU2462157665.USD","IE00BFTCPJ56.SGD","LU0943347566.SGD","SG9999013999.USD","LU2089283258.USD","CANC","LU1145028129.USD","LU2023251221.USD","LU0256863811.USD","LU2491050071.SGD","LU2456880835.USD","IHE","LU2468319806.SGD","LU1804176565.USD","LU2168564149.EUR","SG9999014906.USD","BK4581","SGXZ99366536.SGD","SG9999015978.USD","LU0094547139.USD","LU2552382058.USD","LU0109391861.USD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649758621","title":"Revolution Medicines is Maintained at Outperform by Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2649758621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649758621?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:44","pubTimestamp":1783341840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings(END) Dow Jones NewswiresJuly 06, 2026 08:44 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MFG","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649429629","title":"Revolution Medicines Inc : Mizuho Raises Target Price to $215 from $185","url":"https://stock-news.laohu8.com/highlight/detail?id=2649429629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649429629?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:04","pubTimestamp":1783339444,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","PTH","IE00B4R5TH58.HKD","LU0889565916.HKD","BK4139","IE0009355771.USD","IDNA","CANC","LU0320765992.SGD","IE00B2B36J28.USD","RVMD","IE00BJJMRZ35.SGD","BBH","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649628294","title":"Wedbush Raises Price Target on Revolution Medicines to $181 From $165, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2649628294","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649628294?lang=en_us&edition=fundamental","pubTime":"2026-07-06 18:04","pubTimestamp":1783332258,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $196.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649223642","title":"Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649223642","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649223642?lang=en_us&edition=fundamental","pubTime":"2026-07-06 14:29","pubTimestamp":1783319391,"startTime":"0","endTime":"0","summary":"In early July 2026, Revolution Medicines reported Phase 1/2 data showing that its oral RAS(ON) G12D inhibitor zoldonrasib, in combinations with standard chemotherapy or daraxonrasib, produced high response and disease control rates with manageable safety in metastatic pancreatic ductal adenocarcinoma, supporting ongoing and planned global Phase 3 RASolute trials.\nThe findings highlight how a targeted RAS G12D approach could reshape treatment options in a mutation affecting tens of thousands...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-strong-early-zoldonrasib-pancreatic-data-change-revolut","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-strong-early-zoldonrasib-pancreatic-data-change-revolut","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B2B36J28.USD","LU1861215975.USD","LU1861220033.SGD","IE00B4R5TH58.HKD","CANC","IE00BZ199S13.USD","LU0348723411.USD","LU1854104046.USD","LU0320765992.SGD","IE00BFMHRM44.USD","IE00BFTCPJ56.SGD","LU0124384867.USD","LU1861214812.USD","IE0009355771.USD","LU1854103824.USD","BK4585","LU1548497426.USD","BK4605","BK4588","IE00BD6J9T35.USD","BK4141","BBH","LU2357305700.SGD","ON","LU1861219969.SGD","LU1978683503.SGD","IE00BJT1NW94.SGD","LU0724618433.USD","BK4139","LU2298322129.HKD","LU1720051108.HKD","RVMD","IE0002141913.USD","LU0889565916.HKD","BK4512","LU1983260115.SGD","LU2360107325.USD","PTH","LU1720051017.SGD","LU0109394709.USD","IDNA","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648667815","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648667815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648667815?lang=en_us&edition=fundamental","pubTime":"2026-07-04 01:10","pubTimestamp":1783098608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Johnson & Johnson (J...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-johnson-johnson-jnj-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-johnson-johnson-jnj-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550221.USD","RVMD","PJP","LU0545562505.USD","LU2129689431.USD","JNJ","BMED","GDOC","RXL","JDOC","IE000F7OJYX1.SGD","LU0114720955.EUR","LU2468319806.SGD","IE00BZ1G4Q59.USD","XBI","VHT","MEDX","LU1551013425.SGD","IE00B1BXHZ80.USD","LU2347655156.SGD","LU1057294990.SGD","BBH","BK4585","PTH","LU1059921491.USD","FTXH","HCSG","LU0795875169.SGD","LU0820561909.HKD","LU0889565916.HKD","LU1929549753.HKD","LU2471134952.CNY","IXJ","IE000M9KFDE8.USD","IDNA","LU0943347566.SGD","XLV","IHE","LU1244550577.SGD","IYH","CANC","LABU","LU2750360641.GBP","LU0426417589.USD","IE00BKVL7J92.USD","LU0203347892.USD","FHLC","LU1074936037.SGD","LU1145028129.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648930687","title":"Revolution Medicines is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2648930687","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648930687?lang=en_us&edition=fundamental","pubTime":"2026-07-03 02:37","pubTimestamp":1783017420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings(END) Dow Jones NewswiresJuly 02, 2026 14:37 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648168794","title":"Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2648168794","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648168794?lang=en_us&edition=fundamental","pubTime":"2026-07-03 02:05","pubTimestamp":1783015552,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of $263.00. Charl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/revolution-medicines-strong-zoldonrasib-data-in-g12d-pancreatic-cancer-support-buy-rating-and-unchanged-263-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/revolution-medicines-strong-zoldonrasib-data-in-g12d-pancreatic-cancer-support-buy-rating-and-unchanged-263-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500388","title":"Revolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500388","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648500388?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:40","pubTimestamp":1782996000,"startTime":"0","endTime":"0","summary":"Revolution Medicines reported early trial results showed that its experimental drug zoldonrasib produced strong antitumor activity in two combination regimens for patients with metastatic pancreatic c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861215975.USD","BK4585","LU1720051017.SGD","LU0320765992.SGD","LU0724618433.USD","BK4512","LU1548497426.USD","IE00BZ199S13.USD","LU0889565916.HKD","LU1861219969.SGD","IE00BJJMRZ35.SGD","LU1720051108.HKD","LU2360107325.USD","LU2298322129.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU0124384867.USD","IE00B2B36J28.USD","ON","LU2357305700.SGD","IE0002141913.USD","IE00BFMHRM44.USD","IE00BJT1NW94.SGD","LU1983260115.SGD","BK4139","BK4141","BK4605","LU1978683503.SGD","LU1854104046.USD","IE00B4R5TH58.HKD","RVMD","IE00BD6J9T35.USD","LU0348723411.USD","LU1854103824.USD","LU1861214812.USD","BK4588","LU1861220033.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0318},{"period":"1month","weight":0.1955},{"period":"3month","weight":0.2513},{"period":"6month","weight":0.5175},{"period":"1year","weight":3.8382},{"period":"ytd","weight":1.3095}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0788},{"period":"6month","weight":0.0852},{"period":"1year","weight":0.2013},{"period":"ytd","weight":0.0986}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.003148},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}